M&A / Deals UCB to purchase Neurona and NRTX-1001 for $1.15bn Pharmaceutical Business ReviewThe deal value comprises an upfront payment of up to $650m and up to $500m in future milestones.M&A / DealsNeuroscienceRead full story pharminent April 20, 2026 (Last updated: April 20, 2026) Pharmaceutical Business Review The deal value comprises an upfront payment of up to $650m and up to $500m in future milestones. M&A / DealsNeuroscienceRead full story Post navigation Previous: MSD secures EC approval for Enflonsia to prevent infant RSV infectionNext: Trump backs psychedelics for mental health in new executive order Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
